Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms

Hormone Research
D Wynford-Thomas

Abstract

Tumours of the thyroid follicular cell are proving to be one of the most informative models for "dissecting' the molecular genetics of multi-stage human tumorigenesis. Early thyroid tumour development is closely correlated with mutation of five alternative genes, ras, ret, trk, gsp and the TSH receptor, associated with different tumour phenotypes, providing an excellent example of genotype/phenotype correlation. For two of these genes, ras and ret, there is also direct experimental evidence from gene transfer studies that they are sufficient to initiate tumorigenesis, one of very few situations where such proof of causality has been obtained for a human tumour. Much less is known of the molecular basis of malignant transformation in thyroid. However, the rare, further progression to undifferentiated (anaplastic) cancer provides a particularly clear-cut illustration of the role of the tumour-suppressor gene p53 in human cancer. Furthermore, in vitro data suggest the intriguing possibility that the anaplastic phenotype results from a combination of p53 mutation together with a spontaneous switch in differentiation programme, i.e. co-operation between a genetic and an epigenetic event.

Citations

Mar 13, 1999·International Journal of Cancer. Journal International Du Cancer·C BeimfohrH M Rabes
Jun 16, 2001·The Journal of Pathology·P MatthewsD Wynford-Thomas
Jun 3, 2000·The Surgical Clinics of North America·R L RossiR M Rossi
Feb 13, 2001·Cancer Letters·O Gimm
Sep 16, 2000·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·B Busnardo, D De Vido
Nov 27, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J OriolaF Rivera-Fillat
Aug 30, 2003·Surgical Oncology·Dorry L SegevMartha A Zeiger
Apr 6, 2001·Thyroid : Official Journal of the American Thyroid Association·I BiècheR Lidereau
May 6, 2003·Thyroid : Official Journal of the American Thyroid Association·Daishu MiuraOrlo H Clark
Jun 10, 2004·Thyroid : Official Journal of the American Thyroid Association·Knut Krohn, Ralf Paschke
Dec 16, 1998·Thyroid : Official Journal of the American Thyroid Association·R WinzerJ Köhrle
Aug 30, 2007·Thyroid : Official Journal of the American Thyroid Association·Ana Margarida MeirelesManuel Sobrinho-Simões
Mar 17, 2004·Annals of Surgery·Shoichi KikuchiOrlo H Clark
May 26, 2011·World Journal of Clinical Oncology·Francesco PerriCarlo Buonerba
May 21, 2014·Laboratory Investigation; a Journal of Technical Methods and Pathology·Maria S TretiakovaTracy K Hale
Jan 29, 2008·World Journal of Surgery·Rebecca S SippelOrlo H Clark
Sep 5, 2001·Clinical Endocrinology·K KrohnR Paschke
Aug 26, 2003·The American Journal of Pathology·Andrew H FischerSissy M Jhiang
Aug 10, 2000·The American Journal of Pathology·K M La PerleC C Capen
May 27, 2008·Endocrinology and Metabolism Clinics of North America·Manuel Sobrinho-SimõesPaula Soares
Nov 12, 1998·The American Journal of Pathology·A H FischerD Wynford-Thomas
Oct 23, 2015·Mediators of Inflammation·Marianna Nicoletta Rossi, Fabrizio Antonangeli
Jun 19, 2012·The American Journal of Pathology·Catia GiovanniniLuigi Bolondi
Apr 6, 2001·Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism·F MorettiA Pontecorvi
May 26, 1999·The Journal of Pathology·D Wynford-Thomas
Dec 31, 2016·International Journal of Molecular Sciences·Catia GiovanniniLaura Gramantieri
Sep 25, 2007·Arquivos brasileiros de endocrinologia e metabologia·Vítor TroviscoManuel Sobrinho-Simões
Jan 15, 1999·British Journal of Cancer·D LazzereschiR Mariani-Costantini
Oct 2, 2003·British Journal of Cancer·M V Blagosklonny
Aug 18, 2005·British Journal of Cancer·P PallanteA Fusco
Dec 24, 2004·Endocrine Reviews·Knut KrohnRalf Paschke
Jan 30, 2003·Molecular Endocrinology·Guanjun ChengJudy L Meinkoth
Feb 19, 2002·Oncogene·Arturo P SaavedraJudy L Meinkoth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.